| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5635523 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5674882 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
| US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
|
US5674882 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5635523 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
|
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
Norvir is owned by Abbvie.
Norvir contains Ritonavir.
Norvir has a total of 34 drug patents out of which 26 drug patents have expired.
Expired drug patents of Norvir are:
- US5635523
- US5674882
- US5541206
- US5948436
- US5484801
- US5674882*PED
- US5635523*PED
- US5541206*PED
- US5948436*PED
- US5648497
- US5484801*PED
- US5648497*PED
- US6037157
- US6703403
- US6037157*PED
- US6703403*PED
- US6232333
- US6232333*PED
- US7148359
- US7148359*PED
- US7141593
- US7432294
- US7364752
- US7432294*PED
- US7141593*PED
- US7364752*PED
Norvir was authorised for market use on 10 February, 2010.
Norvir is available in tablet;oral, solution;oral, capsule;oral dosage forms.
Norvir can be used as treatment of hiv infection in combination with other antiretroviral agents, treatment of hiv-infection in combination with other antiretroviral agents, treatment of hiv in concomitant therapy, use of ritonavir in combination with any reverse transcriptase inhibitor.
The generics of Norvir are possible to be released after 17 March, 2027.
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: Use of ritonavir in combination with any reverse transcriptase inhibitor; Treatment of hiv infection in combination with other antiretroviral agents; Treatment of hiv-infection in combination with oth...
Dosage: TABLET;ORAL; SOLUTION;ORAL; CAPSULE;ORAL
NORVIR family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541206 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBOTT | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
|
US5541206 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBOTT | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5635523 | ABBOTT | Retroviral protease inhibiting compounds |
Jun, 2014
(9 years ago) | |
| US5648497 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5635523 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Dec, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
Norvir is owned by Abbott.
Norvir contains Ritonavir.
Norvir has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Norvir are:
- US5541206
- US5948436
- US5541206*PED
- US5948436*PED
- US5635523
- US5648497
- US5635523*PED
- US5648497*PED
Norvir was authorised for market use on 01 March, 1996.
Norvir is available in capsule;oral dosage forms.
Norvir can be used as use of ritonavir in combination with any reverse transcriptase inhibitor, use of norvir to inhibit hiv protease or to inhibit an hiv infection.
The generics of Norvir are possible to be released after 15 January, 2015.
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 01 March, 1996
Treatment: Use of norvir to inhibit hiv protease or to inhibit an hiv infection; Use of ritonavir in combination with any reverse transcriptase inhibitor
Dosage: CAPSULE;ORAL
NORVIR family patents